Bayer Vardenafil Booth At Urological Meeting Revised Following FDA Request
Bayer revised a vardenafil display at the American Urological Association meeting following communications with FDA's ad division.
You may also be interested in...
Maxim's Ceplene promotions at the American Society of Clinical Oncology conference in May are the subject of the second letter to the company from FDA's ad division in less than six months.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials